Clarification on "EFSA Genetically Engineered Crop Composition Equivalence Approach: Performance and Consistency"
Rod A Herman1,2, Nicholas P Storer1, Carl Walker2
1Corteva Agriscience, 9330 Zionsville Road, Indianapolis, Indiana 46268, United States.
Abstract:
A recent perspective defends the approach of the European Food Safety Authority (EFSA) for evaluating the compositional normality of genetically engineered (GE) crops using a concurrently grown subset of non-GE varieties within the risk assessment. While the approach of the EFSA manages the risk of falsely claiming equivalence, this is achieved at the expense of low power to detect true equivalence. This generates inconsistent findings and safety conclusions across studies for the same GE event based on the selected non-GE comparators. Because variation in GE crop composition has not been associated with safety, we suggest policy improvements that would better align with consumer protection.
Related Concept Videos
Bioequivalence: Overview
Pharmaceutical Equivalents
Equivalence: In Vitro and In Vivo Bioequivalence
Bioequivalence of Drugs: Drugs with Multiple Indications
Plant Breeding and Biotechnology
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence


